SUMMARY The effect of cimetidine on normal human gastric mucus has been compared with that of carbenoxolone, a drug believed to enhance mucus production. Each drug was given for two weeks, the gastric contents aspirated over a timed period and the results assessed in unstimulated and pentagastrin stimulated secretions. The volume, dry weight and the carbohydrate contents of nondiffusable glycoconjugates, high molecular mass glycoproteins and glycopolypeptides were investigated. Both drugs reduced the volumes of stimulated secretions. This was statistically significant after cimetidine. More importantly neither drug affected the amount of non-diffusable glycoconjugates, so that the concentration remained the same or increased. Both drugs reduced the monosaccharide content of the high molecular mass fractions. This reached significance for the stimulated secretion after cimetidine. As the carbohydrate content of the glycopolypeptides was unchanged this indicated the presence of a non-mucin glycoprotein or protein. Overall there was no fundamental difference between the results for cimetidine and carbenoxolone.
The mechanism by which carbenoxolone promotes ulcer healing remains obscure. It is believed to enhance mucus release thereby increasing mucosal resistance to acid, pepsin, and other harmful substances. Cimetidine, one of the more efficacious antiulcer drugs, acts by blocking H2-receptors. While most reviews record no effect on mucus, Guslandi et al' suggest that recurrence of ulcers after cimetidine treatment was partly caused by the damaging effect on mucus.
In the living human subject, it is not possible to obtain adherent mucus except from gastrectomy specimens. Studies on gastric mucus in health and disease are usually carried out on aspirated material which contains other glycoconjugates and proteins. Many earlier studies of the effect of drugs on gastric mucus have measured concentrations of individual monosaccharides in the total secretion. It was decided therefore to use more specific techniques by carrying out a total carbohydrate analysis and by fractionating the aspirated material into its various components. This study therefore applied these procedures to evaluate the effects of chronic adminis-tration of carbenoxolone or cimetidine on gastric mucus in normal human subjects.
Methods

SUBJECTS
Eight male and eight female subjects aged 18-28 years gave informed consent for the study which was approved by the ethical committee of the United Bristol Hospitals. The subjects were healthy, the women were not pregnant or lactating, and none were taking any drugs. Alcohol was not permitted for one week before, or during the study. The subjects were randomly allocated to two groups each consisting of four men and four women.
Each subject had gastric function studies carried out on two separate days. On (10) 52 (13) 48 (12) 51 (10) n=8; mean (SE); *2p<0-05. While there is little doubt about the effectiveness of carbenoxolone in healing gastric ulcers, its mechanism of action is uncertain. It reportedly increases the life span of gastric epithelial cells" and reduces the rate of loss of 3H-thymidine labelled gastric epithelial cells in acutely stressed rodents.'2 Carbenoxolone has also been associated with changes in the monosaccharide content of aspirated gastric mucus. In view of the above comments, however, these findings must remain questionable.
Guslandi and colleagues' '4'`studied the effect of various antiulcer drugs and concluded that carbenoxolone enhanced mucus whereas cimetidine damaged it and further suggested that this may be the reason for the relapses after cimetidine treatment. This work was, however, based on concepts published in 1967'5 that gastric mucus can be separated into meaningful entities and that the acidic glycoproteins are more protective. Most biochemists in this field would not accept the simplicity of these ideas.
In the present study no important differences were (17) 85 (21) 90 (28) Mean (SE). These analyses apply only to the material excluded (S1) from Sephadex G 150 after pronase digestion. Tables 5 and  6 , however, show that the carbohydrate of mucus glycopolypeptide is not decreased after administration of the two drugs, excluding the first of these two possibilities. The likelihood is therefore that a nonmucin component is present. Several proteins have been described in association with mucus some of which are important in the polymeric structure. '6 In support of this, the 280 nm absorption characteristic of protein was increased in the SI fraction after both drugs but to a greater extent with cimetidine.
The analyses of the glycopolypeptides are given in Tables 5 and 6 . The only significant difference is in the N-acetylgalactosamine content after carbenoxolone in the unstimulated secretions. The result before drug (Table 6 ) is, however, anomalously low whereas the after drug result is comparable with the other analyses. The interpretation of this change is therefore difficult. The results obtained for carbenoxolone are interesting in view of the suggestions that a major mode of action of this drug is by enhancement of the mucus barrier.'7 "8 No important differences were found between before drug results and after drug nor between carbenoxolone and cimetidine. The assertion that cimetidine damages mucus' 1314 is not supported by any of these results.
This study was carried out to assess the effect of two important ulcer-healing drugs on gastric mucus in normal subjects. The lack of spectacular results must be interpreted in terms of individuals who are already fully 'cytoprotected' and who would not be expected to show marked changes. The study does nevertheless provide a baseline for the investigation of patients with peptic ulcer in whom the mucus layer might be defective and which might be restored to normal by the drugs.
